Sachs Associates’ Post

🌌 Key Differentiators between BPGbio, Inc.'s NAi platform and other platforms 🌌 The NAi platform consists of an industry leading and clinically annotated proprietary biobank, with purpose-built causal AI and is using the world’s fastest supercomputer, Frontier, at Oak Ridge National Laboratory (ORNL), making it a pioneer in the fully-integrated high performance computing (HPC) platform in the biopharmaceutical industry for AI-driven target nomination, development, and molecule design. The NAi platform has important differentiators in strategy, data sourcing, AI models, computing, validation and outcome. For more information about BPGbio, Inc.'s NAi platform visit: https://lnkd.in/gvTXPEEf 👉 PARTNER WITH US ON YOUR DRUG DEVELOPMENT JOURNEY! #NAiInterrogativeBiology #AI #Biotechnology #Multiomics #SpatialOmics #Oncology #Neurology #RareDisease #Cancer #Biomarker #Biopharma #Techbio #Biotech #TPD #MitochondrialMedicine #ProteinHomeostasis #Proteostasis #DrugDiscovery #Therapeutics

Roca Therapeutics is a biotech start-up headquartered in Nice, France, with a groundbreaking ophthalmology program. Our lead candidate, RCT002, is less than 18 months from IND/CTA submission and has shown promising pharmacological data. Developed for topical administration, RCT002 offers a unique pharmaco-economic profile. It complements the current standard of care administered via intravitreal injections (meaning no direct competition), potentially modifying the disease by blocking resistant angiogenesis, oxidative stress, inflammation, and fibrosis. RCT002 is backed by solid translational and mechanistic data. We have designed a robust disease, clinical, and regulatory strategy targeting Radiation-induced Maculopathy (an orphan niche market for accelerated approval) and Diabetic Macular Edema (upside market opportunity). Roca Therapeutics has already secured a international VC (3B Future) for the seed financing who is now looking to co-lead the current Series A funding round to develop RCT002 until the end of Phase 2a (and extend the pipeline). We believe RCT002 represents a compelling investment opportunity. Meet Roca Therapeutics @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

FluoSphera is a patent-protected technology platform developing a unique set of disruptive technologies mimicking the clinical response to drugs under systemic conditions to accurately predict drug safety and efficacy. Such high-throughput systemic assays reliably identify the most promising lead compounds early during drug discovery to decrease drug development failure in the clinic, thus increasing the chance for the patients to get access to the best therapeutics while reducing animal experimentation. Meet FluoSphera @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

FDA granted approval to Iovance Biotherapeutics, Inc.’ s lifileucel as the first one-time cell therapy for a solid tumor and the first tumor-infiltrating lymphocytes (TIL) therapy. Amtagvi, as lifileucel will be known commercially, was approved under the FDA's Accelerated Approval pathway, which allows the greenlighting of medicines for serious or life-threatening diseases based on surrogate endpoints that are reasonably likely to predict clinical benefit. Read: https://lnkd.in/e_Y9SwR3 #sciencesdelavie #biotechnologie #biotechnology #innovation #innovations #recherche #sciences #medicaments #research #drugresearch #laboratories #labs #chemistry #chimie #biology #biologie #biopharma #rna #rnatherapeutics #arn #wewillwin

🔬 𝐀𝐧 𝐨𝐯𝐞𝐫𝐯𝐢𝐞𝐰 𝐨𝐟 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐚𝐥 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐬 (𝐀𝐓𝐌𝐏𝐬) 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐛𝐲 𝐭𝐡𝐞 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 𝐀𝐠𝐞𝐧𝐜𝐲 🔬 Currently, there are 19 ATMPs approved for use in the European market, including: 💉 15 gene therapy medicines (GTMP)  🧬 2 somatic-cell therapy medicines (CTMP)  🔬 2 tissue-engineered medicines The applications include: 💉 Haematology (10)  🧠 Neurology (3)  👁️ Ophthalmology (2)  🍽️ Gastroenterology (1)  🛡️ Immunodeficiency (1)  💪 Musculoskeletal (1)  🩺 Oncologic (1) 12 of these ATMPs are also approved under the same name by the FDA. Source: Joanna Sadowska #pharma #EMA #FDA #GeneTherapy #SomaticCellTherapy #TissueEngineering #Healthcare #Medicine #Europe #FDAApproval #Innovation #Biotechnology #pharmaceutical #drugdevelopment

FDA granted approval to Iovance Biotherapeutics, Inc.’ s lifileucel as the first one-time cell therapy for a solid tumor and the first tumor-infiltrating lymphocytes (TIL) therapy. Amtagvi, as lifileucel will be known commercially, was approved under the FDA's Accelerated Approval pathway, which allows the greenlighting of medicines for serious or life-threatening diseases based on surrogate endpoints that are reasonably likely to predict clinical benefit. Read: https://lnkd.in/efYg8kSp #sciencesdelavie #biotechnologie #biotechnology #innovation #innovations #recherche #sciences #medicaments #research #drugresearch #laboratories #labs #chemistry #chimie #biology #biologie #biopharma #rna #rnatherapeutics #arn #wewillwin

☑️ *READ DESCRIPTION BELOW:* Part 1: llustration of the miRNA-based drug discovery and development process beginning from target identification and miRNA discovery to FDA-approved miRNA therapeutics on the market. In the traditional drug development process, the timeline from target identification and drug discovery to phase 1–3 human clinical trials and, ultimately, FDA approval, followed by phase 4 studies, can go on for several years. Conversely, RNA-based and, more specifically, miRNA-based drug discovery and development can potentially mitigate attrition rates, time constraints, and costs. The initial phase in developing miRNA therapeutics involves systematically selecting potential miRNA candidates by analyzing patient samples and validating their relevance to a particular disease of interest through tissue culture and in vivo models. Various publicly available genomic and proteomic databases from diverse healthy and diseased tissues can aid in identifying promising miRNA candidates when combined with biological validation(...) https://lnkd.in/e38EDpjA #Gesundheit #Bildung #Fuehrung #Coaching #Mindset #Motivation #Gehirn #Neuroscience #Psychologie #Persoenlichkeitsentwicklung #Kindheit #KeyNoteSpeaker #Humangenetik #Biochemie #Neuroleadership #Ernaehrung #Transformation #Stress #Demografie #Gender #Age #interkulturelleKompetenz #Epigenetik #Veraenderung #EmotionaleIntelligenz #Change #Gesellschaft #Organisationsentwicklung #Philosophie #Beratung # Quantum

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Phialogics concept is based on the targeted modification of immunoglobulin receptor domains (IgVs) to modulate immune response in inflammatory diseases. IgV mediated receptor-ligand interaction represents a significant source of novel biologics. Phialogics lead molecules replicate endogenous protein-protein interactions to efficiently modulate the function of their target receptor. So far, only this unique platform technology can achieve such a high level of precision. Meet Phialogics AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

Cell And Gene Therapy Market Size, Share & Trends Analysis Report By Therapy Type (Gene Therapy, Cell Therapy), By Application (Oncology, Genetic Disorders, Dermatology Disorders, Musculoskeletal Disorders, Others), By End-Users (Hospitals, Cancer Care Centers, Wound Care Centers, Others), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028. Global Cell And Gene Therapy Market size was valued at USD 1182.96 Million in 2021 and is projected to reach USD 6598.25 Million by 2028, growing at a CAGR of 19.82% from 2021 to 2028 according to a new report by 𝐈𝐧𝐭𝐞𝐥𝐥𝐞𝐜𝐭𝐮𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡.   𝐘𝐨𝐮 𝐜𝐚𝐧 𝐜𝐡𝐞𝐜𝐤 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:⬇ https://lnkd.in/dSgRAksV 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐖𝐨𝐫𝐤𝐢𝐧𝐠 𝐈𝐧 𝐓𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭:⬇ Diamond Pharma (Acquired by ProPharma) DiscGenics EastHORN (Acquired by Novotech) Emmes ERGOMED Evotec Excelya Fast-Track Drugs & Biologics, LLC FGK Clinical Research GmbH Forge Biologics Frontage Laboratories, Inc Genesis Biotechnology Group GeneWerk GenoSafe Genprex, Inc. Genpro Research Global Center for Medical Innovation - GCMI Gsap HebeCell Corp Helixmith HemaCare Corporation, a Charles River Company HemoGenix, Inc ICON plc ICRC-Weyer GmbH Imanis Life Sciences